Intractable & Rare Diseases Research | Importance of Early Diagnosis and Cardiac Complication Screening for MPS IVA

Recommend:

This article highlights the importance of early screening in improving diagnostic efficiency and reducing mortality risk through a case of delayed diagnosis of MPS IVA, offering critical insights for clinical practice.

 

Literature Overview
This article, 'Early screening for respiratory and cardiac complications in pediatric mucopolysaccharidosis IVA: Insights from a case,' published in the journal Intractable & Rare Diseases Research, reviews a fatal case of MPS IVA in a child due to delayed diagnosis and lack of timely intervention for cardiac and respiratory complications. It emphasizes the value of combining early genetic testing with enzyme activity assays in improving diagnostic efficiency and recommends early cardiopulmonary screening after diagnosis.

Background
Mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome, is an autosomal recessive disorder caused by mutations in the GALNS gene, leading to a deficiency of N-acetylgalactosamine-6-sulfate sulfatase and resulting in glycosaminoglycan (GAG) metabolic dysfunction. The disease is characterized by skeletal dysplasia, joint hypermobility, coarse facial features, and cardiopulmonary dysfunction. Cardiac involvement, particularly valvular heart disease and pulmonary arterial hypertension, is one of the major risk factors for mortality. Due to high clinical heterogeneity and subtle early symptoms, MPS IVA is often misdiagnosed or missed, leading to treatment delays. Although enzyme activity assays and genetic sequencing technologies are gradually being adopted, many medical institutions still lack standardized screening protocols and systematic evaluation tools. This study explores how to optimize the diagnostic process and enhance cardiopulmonary monitoring after diagnosis by analyzing a real-world case.

 

Used to compare genetic sequence differences between species or populations, suitable for evolutionary analysis.

Learn More

 

Research Methods and Experiment
The research team conducted a retrospective analysis of clinical data from an 11-year-old male patient diagnosed with MPS IVA, and used exome sequencing to identify two heterozygous variants in the GALNS gene. The case analysis focused on delayed diagnosis, the insidious progression of cardiac complications, and the eventual acute respiratory failure. Additionally, the study reviewed other GALNS variants reported in the literature, further underscoring the critical role of genetic testing in diagnosis.

Key Conclusions and Perspectives

• Delayed diagnosis is one of the key factors contributing to poor prognosis in MPS IVA patients.
• Cardiac valvular disease and pulmonary arterial hypertension may present with no obvious symptoms in early stages; therefore, enhanced screening is necessary.
• Combining enzyme activity assays with genetic testing can significantly reduce diagnostic time.
• Cardiopulmonary evaluation and intervention should be initiated immediately after diagnosis.
• Improving genotype-phenotype databases can enhance the accuracy of diagnosis and treatment evaluation.

Significance and Future Directions
This study illustrates the challenges in the diagnostic pathway of MPS IVA and proposes strategies for improvement, including early genetic screening, systematic cardiopulmonary evaluation, and enzyme replacement therapy. Future studies may explore the role of multi-center collaboration in early diagnosis and develop standardized screening protocols to reduce misdiagnosis rates.

 

Assesses the pathogenic potential of genetic variants, providing a reference for variant function analysis.

Learn More

 

Conclusion
MPS IVA is a rare disease that presents significant diagnostic challenges in clinical settings, particularly in the absence of early screening mechanisms, which can lead to severe cardiopulmonary complications and life-threatening outcomes. Through the analysis of a fatal case caused by delayed diagnosis, this study alerts clinicians to perform early genetic and enzyme activity testing when encountering children presenting with unexplained skeletal dysplasia and growth retardation. Moreover, systematic cardiopulmonary assessment and timely intervention after diagnosis are essential to slow disease progression. Optimizing the diagnostic process not only improves diagnostic efficiency but also provides more precise guidance for subsequent treatments, ultimately enhancing both survival rates and quality of life for patients.

 

Haiyan Shu, Xiaohong Shang, Yan Sun, Chen Chen, and Jianmei Yang. Early screening for respiratory and cardiac complications in pediatric mucopolysaccharidosis IVA: Insights from a case. Intractable & Rare Diseases Research.